Analyst Ratings for Taysha Gene Therapies (TSHA)
TSHA Rating Summary
TSHA Price Target Summary
- Highest: $14.00 (Canaccord)
- Lowest: $8.00 (Citizens)
- Average: $11.25
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$11.25 (+146.2%)
* Over Last 12-Mos
Rating Score: 8.9 / 10
Percentile Rank: 89%
Avg. $ Target:
$11.25 (+146.2%)
* Over Last 12-Mos
Rating Score: 8.9 / 10
Percentile Rank: 89%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/4/2025 | Goldman Sachs | Salveen Richter | Upgrade | Buy (Early-Stage Biotech) |
11.00 (N/A) |
4.49 (4.57) |
1.78% | Details |
| 10/21/2025 | Raymond James » Updated 1/6/2026 |
Chris Raymond | New Coverage | Strong Buy (N/A) |
13.00 (N/A) |
4.72 (4.57) |
-3.18% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
